imukan™ 120 mg betox-93® vitamin d3 immune system (2017.) kapsula
natures s.r.o. vai sia „medpro nutraceuticals” - kapsula
olimp® sport nutrition system protein 80® (2016.) pulveris
olimp laboratories sp. z.o.o. - pulveris
vitamin c slow release system (paziņots 2013.) tablete
helvetia direct marketing s.r.o. - tablete
christian™ satin system (paziņots) kapsula
new nordic manufacturing aps - kapsula
rinvoq
abbvie deutschland gmbh & co. kg - upadacitinib - artrīts, reimatoīds - imūnsupresanti - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
saphnelo
astrazeneca ab - anifrolumab - sarkanā vilkēde, sistēmiska - imūnsupresanti - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.
doppelherz® system magnesium 500 depot + b-vitamine (2022.) tablete
tablete
forever® dx4™ body balancing system (2022.) cits, tabletes, košļājamās tabletes, putojošās tabletes un pulveris
cits, tabletes, košļājamās tabletes, putojošās tabletes un pulveris
slimbel system 3 (2023.) kapsula
kapsula